Bausch + Lomb (NYSE:BLCO) Issues Earnings Results, Beats Expectations By $0.02 EPS

Bausch + Lomb (NYSE:BLCO - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02, Zacks reports. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.34% and a negative net margin of 6.62%. The company's revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.24 earnings per share. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Price Performance

Bausch + Lomb stock traded down $0.15 during midday trading on Friday, reaching $15.75. The company's stock had a trading volume of 589,705 shares, compared to its average volume of 678,649. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The stock's 50 day simple moving average is $17.42 and its 200 day simple moving average is $18.13. The firm has a market capitalization of $5.55 billion, a PE ratio of -17.30, a P/E/G ratio of 2.17 and a beta of 0.46.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BLCO shares. Bank of America decreased their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a report on Thursday. Stifel Nicolaus decreased their price objective on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Thursday, January 16th. Citigroup downgraded Bausch + Lomb from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Bausch + Lomb in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $19.83.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.